Patents Issued in March 7, 2024
  • Publication number: 20240075039
    Abstract: Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administration, quick and high-efficient release, no particular requirements on equipment, and a simple formulation preparation process, can ensure formulation stability and facilitate transportation and storage, and is suitable for large-scale production.
    Type: Application
    Filed: November 13, 2023
    Publication date: March 7, 2024
    Inventors: Gang QIU, Yiwei SHEN, Wenyuan FAN, Shuo XU, Huiru LV, Jialin BIAN, Zhengming DU
  • Publication number: 20240075040
    Abstract: This disclosure relates to ruxolitinib, or a pharmaceutically acceptable salt thereof, and its use in treating prurigo nodularis.
    Type: Application
    Filed: November 2, 2023
    Publication date: March 7, 2024
    Applicant: INCYTE CORPORATION
    Inventor: Paul SMITH
  • Publication number: 20240075041
    Abstract: The present invention relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of an eosinophilic disorder, including hypereosinophilic syndrome.
    Type: Application
    Filed: October 5, 2020
    Publication date: March 7, 2024
    Inventor: Brenton Mar
  • Publication number: 20240075042
    Abstract: The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1 or Compound No. 2: or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.
    Type: Application
    Filed: November 2, 2021
    Publication date: March 7, 2024
    Inventors: Elizabeth BUCK, Matthew O'CONNOR, Darlene ROMASHKO, Tai-An LIN, Alexander FLOHR, Luca ARISTA, Iwona WRONA, Matthew LUCAS, Chris ROBERTS, Giorgio OTTAVIANI, Sherri SMITH, Nigel WATERS
  • Publication number: 20240075043
    Abstract: An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 7, 2024
    Applicant: Red Mountain Med Spa, LLC
    Inventor: Suzanne Bentz
  • Publication number: 20240075044
    Abstract: The present disclosure pertains to a particulate co-processed pre-formulated excipient composition and methods for producing the same. In particular, the present disclosure provides a particulate co-processed pre-formulated excipient composition for enhancing dissolution rate of poorly soluble active pharmaceutical ingredient, wherein said excipient composition comprises a co-processed mixture of a filler-binder, a glidant, a disintegrant, a solubility enhancer, and a lubricant. The co-processed pre-formulated excipient composition has higher bulk density, bigger particle size, excellent flowability, good physical properties of excipient delivered good quality of tablet in terms tablet hardness, disintegration time and dissolution rate.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 7, 2024
    Applicant: Sigachi Industries Limited
    Inventors: Amit Raj Sinha, Monika Tomar, Rauf Pathan
  • Publication number: 20240075045
    Abstract: Compositions and methods of treating pericarditis and preventing recurrent pericarditis are provided.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 7, 2024
    Inventors: Indu MUNI, Neal MUNI, Naomi VISHNUPAD
  • Publication number: 20240075046
    Abstract: The present invention provides a pharmaceutical composition including one or more cannabinoids, and methods of using same, such as for treating estrogen receptor-related diseases. The present invention further provides combination therapy comprising one or more cannabinoids and an estrogen receptor activation inhibitor and use thereof in sensitizing subjects that are resistance to treatment with the estrogen receptor activation inhibitor alone.
    Type: Application
    Filed: December 27, 2021
    Publication date: March 7, 2024
    Inventors: David Meiri, Vered Cohen
  • Publication number: 20240075047
    Abstract: Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 7, 2024
    Inventors: Robert Vito FARESE, Mini Paliyath SAJAN, Margaret Genevieve HIGGS
  • Publication number: 20240075048
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Application
    Filed: October 18, 2023
    Publication date: March 7, 2024
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Publication number: 20240075049
    Abstract: In alternative embodiments, provided are drugs, therapeutic combinations and methods for preventing or ameliorating, or decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, a viral infection such as a coronavirus infection or a microbial infection including a protozoan, helminthiasis, insect and/or parasitic infection such as: malaria that can be caused by a parasite of the genus Plasmodium; filariasis, leprosy or streptocerciasis that can be caused by a parasite of the superfamily Filarioidea; leprosy that can be caused by a parasite of the genus Mycobacterium; river blindness or onchocerciasis that can be caused by parasitic worms such as parasites of the genus Onchocerca; hookworm or roundworm infections that can be caused by parasites of the genus Ancylostoma or Necator; trichuriasis or whipworm infection that can be caused by a parasite of the genus Trichuris; roundworm or an Ascaris infections; mite-carried infections such as scabies; infections suc
    Type: Application
    Filed: December 20, 2021
    Publication date: March 7, 2024
    Inventor: Thomas Julius BORODY
  • Publication number: 20240075050
    Abstract: The present invention relates to methods and compositions for treating an LRRK2-associate disorder or condition, e.g., Parkinson's Disease, methods for reducing or preventing neuronal cell death, and methods for reducing neurodegeneration and/or neuroinflammation, in a subject in need thereof, by an agent that decreases the expression of LRRK2, e.g., an agent that induces LRRK2 mRNA decay.
    Type: Application
    Filed: July 25, 2023
    Publication date: March 7, 2024
    Applicant: University of Connecticut
    Inventors: Yulan Xiong, Jianzhong Yu, Qinfang Liu
  • Publication number: 20240075051
    Abstract: The invention concerns a trans-splicing RNA (tsRNA) molecule comprising one or multiple unstructured binding domains; a cell or vector comprising said tsRNA; and a method for killing cells or treating a disease using said tsRNA.
    Type: Application
    Filed: November 10, 2022
    Publication date: March 7, 2024
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Volker PATZEL, Sushmita PODDAR
  • Publication number: 20240075052
    Abstract: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 7, 2024
    Inventor: Jared A. Gollob
  • Publication number: 20240075053
    Abstract: The present invention relates to anti-ROR2 inhibitors and uses thereof in treating and/or preventing cartilage loss.
    Type: Application
    Filed: June 29, 2023
    Publication date: March 7, 2024
    Inventors: Francesco DELL'ACCIO, Anne-Sophie THORUP
  • Publication number: 20240075054
    Abstract: A pharmaceutical sterile composition consisting of hyaluronic acid sodium salt and Hyaff11p50 and related use in the intravesical treatment of interstitial cystitis or Bladder Pain Syndrome (IC/BPS), of acute cystitis following bacterial infection, trauma or urolithiasis, of cystitis caused by radiation, chemotherapy, and hemorrhagic cystitis, as well as in the treatment of the bladder of patients undergoing endoscopic resection of benign or malignant bladder tumour at risk of relapse, are described.
    Type: Application
    Filed: October 22, 2020
    Publication date: March 7, 2024
    Applicant: FIDIA FARMACEUTICI S.P.A.
    Inventors: Carlo PIZZOCARO, Anna Maria ZANELLATO, Mauro PAVAN
  • Publication number: 20240075055
    Abstract: Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.
    Type: Application
    Filed: December 22, 2021
    Publication date: March 7, 2024
    Applicants: University of Virginia Patent Foundation, The University of Manchester
    Inventors: William A. Petri, JR., Alexandra N. Donlan, Judith E. Allen, Tara Elaine Sutherland, Anthony John Day
  • Publication number: 20240075056
    Abstract: Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.
    Type: Application
    Filed: October 5, 2023
    Publication date: March 7, 2024
    Inventors: Yoo Sin Park, Il Hoon Lee
  • Publication number: 20240075057
    Abstract: Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites. Mannosylated carbohydrate polymers are synthesized to be modified to be either polyanionic (i.e., net negatively charged) or electrostatically neutral, and using these polyanionic or neutral mannosylated carbohydrate polymers as competitors for polycationic (i.e., net positively charged) mannosylated carbohydrate polymers carrying small molecule drug payloads or imaging moieties to CD206 expressing cells in target tissues, such as tumors or other sites of inflammation.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: David A. Ralph, Jeffrey Scott Arnold
  • Publication number: 20240075058
    Abstract: The use of a composition which comprises lignosulfonate for the prevention and treatment of pathogenic and medical disorders in humans and animals. In some embodiments the composition is substantially free of elemental sulphur. In some embodiments the lignosulfonate is radically polymerized. In some embodiments the composition is formulated as an animal feed additive or supplement. The disclosure also encompasses a method of preventing or treating a pathogenic or medical disorder in a human or animal subject by administering the composition to the subject in an effective dose to attenuate the pathogenic effect of a pathogen or other biological agent, thereby enabling the subject to mount an effective immune response to the pathogen or other biological agent.
    Type: Application
    Filed: September 20, 2023
    Publication date: March 7, 2024
    Inventors: Ralph Kevin Walker, Sudha Bhavanam
  • Publication number: 20240075059
    Abstract: The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.
    Type: Application
    Filed: January 19, 2022
    Publication date: March 7, 2024
    Inventors: Joshua Thomas CLAYPOOL, Ghislain SCHYNS, Carrie Louise WALK
  • Publication number: 20240075060
    Abstract: The present invention relates to an oral solid formulation for colon cleansing, wherein the oral solid formulation minimizes side effects, has excellent dosing convenience and medication compliance, enables a pharmaceutical effect to be exhibited quickly, and has excellent colon cleansing ability.
    Type: Application
    Filed: December 30, 2021
    Publication date: March 7, 2024
    Applicant: TAEJOON PHARMACEUTICAL CO., LTD.
    Inventors: Joon Youb LEE, Wan GU, Woo Young JANG, Young Un KIM, Yong Jun KIM
  • Publication number: 20240075061
    Abstract: The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.
    Type: Application
    Filed: December 13, 2022
    Publication date: March 7, 2024
    Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Wensheng Wang, Dongqi Chen, Chengfei Pu, Zhao Wu, Lei Xiao, Zhiyuan Cao, Le Tian
  • Publication number: 20240075062
    Abstract: The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as cancers.
    Type: Application
    Filed: March 3, 2023
    Publication date: March 7, 2024
    Inventors: Kole T. ROYBAL, Raymond LIU, Iowis ZHU
  • Publication number: 20240075063
    Abstract: The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated Invariant T cells (MAIT cells), a population of unconventional T cells that exhibit potent antibacterial activity, expressing a semi-invariant TCR which recognizes vitamin B2 derivatives of microbial origin presented by the MR1 molecule. In particular, the inventors used i) an allogenic reaction model in vitro (mixed lymphocyte reaction, MLR) and ii) murine model of xenogeneic aGvHD They first verified that human MAIT cells do not proliferate in response to allogeneic stimulation in vitro (MLR) or in vivo (immunodeficient mice) alone but require for their expansion both an inflammatory environment and TCR ligation by its ligand. In contrast, MAIT cells are able to inhibit the proliferation of allospecific LT in vitro in a dose-dependent manner. Furthermore, the adoptive transfer of MAIT cells in a mouse model of xeno-GVHD resulted in a delay in early or late GvHD development.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 7, 2024
    Inventors: Sophie CAILLAT-ZUCMAN, Nana TALVARD-BALLAND
  • Publication number: 20240075064
    Abstract: The present disclosure provides compositions and methods for expanding T cells or tumor infiltrating lymphocytes (TILs) in vitro. K562 feeder cells engineered to express a costimulatory molecule (e.g., 41BB ligand (41BBL)) and either interleukin 21 (IL21) or interleukin 7 (IL7) can be used in a rapid expansion protocol (REP) step to expand the T cells or TILs. Thus, provided herein is a culture comprising T-cells or TILs and modified K562 feeder cells. The T cells can be modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) or the TILs can be modified to express membrane-bound IL15 (mbIL15). The T cells or TILs can be expanded in vitro using aREP without the use of exogenous interleukin 2 (IL2), and the expanded cells can be used in adoptive cell therapy for treatment of cancer without concomitant use of an exogenous cytokine such as IL2.
    Type: Application
    Filed: January 18, 2022
    Publication date: March 7, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Kutlu Goksu Elpek, Celeste Richardson, Michelle Lois Fleury, James Alex Storer, Shyamsundar Subramanian, Mithun Khattar
  • Publication number: 20240075065
    Abstract: The present invention relates to a modified T cell, comprising (a) a disrupted endogenous CD28-encoding gene; and (b) a polynucleotide encoding a chimeric antigen receptor (CAR), wherein the CAR comprises in its ectodomain at least one antigen binding moiety that is capable of specific binding to the extracellular portion of CD28. The invention furthermore relates to a population of the modified T cells, to a method for generating modified T cells and medical and non-medical uses thereof.
    Type: Application
    Filed: May 22, 2023
    Publication date: March 7, 2024
    Inventors: Tobias FEUCHTINGER, Semjon WILLIER
  • Publication number: 20240075066
    Abstract: The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.
    Type: Application
    Filed: May 24, 2023
    Publication date: March 7, 2024
    Inventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Matteo Righi
  • Publication number: 20240075067
    Abstract: The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.
    Type: Application
    Filed: June 23, 2023
    Publication date: March 7, 2024
    Inventors: Yuta ANDO, Julyun OH, Han XU, Carl Alexander Kamb
  • Publication number: 20240075068
    Abstract: Novel soluble ?T-cell receptor chains, soluble ?T-cell receptor chains, soluble ??TCRs, or fragments thereof, mediating anti-tumour responses or anti-infective responses are provided.
    Type: Application
    Filed: July 17, 2023
    Publication date: March 7, 2024
    Inventors: Thijs Van Montfort, Haakan Norell
  • Publication number: 20240075069
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 7, 2024
    Inventors: Philip Stewart LOW, Haiyan CHU, Yingjuan June LU, Christopher Paul LEAMON, Leroy W. WHEELER, II, Michael C. JENSEN, James MATTHAEI
  • Publication number: 20240075070
    Abstract: The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of the tumor microenvironment.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 7, 2024
    Applicant: The General Hospital Corporation
    Inventors: Marcela V. Maus, Bryan Choi
  • Publication number: 20240075071
    Abstract: Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved.
    Type: Application
    Filed: November 23, 2022
    Publication date: March 7, 2024
    Inventors: Ruei-Yue Liang, Kai-Ling Zhang, Ming-Hsi Chuang, Po-Cheng Lin, Peggy Leh Jiunn Wong, Chia-Hsin Lee
  • Publication number: 20240075072
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, containing, as an active ingredient, stem cells overexpressing SOD3. The present inventor has ascertained that mesenchymal stem cells (MSCs) overexpressing SOD3 have a stronger antioxidant activity and immune regulatory function than normal MSCs, and thus the MSCs overexpressing SOD3 can be an effective treatment agent for inflammatory diseases, autoimmune diseases, organ transplant rejection and the like.
    Type: Application
    Filed: June 14, 2023
    Publication date: March 7, 2024
    Inventors: Kyung Sun Kang, Tae Yoon Kim
  • Publication number: 20240075073
    Abstract: This document provides materials and methods for treating a damaged optic nerve in a mammal to restore visual function comprising administering a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This document also provides materials and methods for determining a remyelination potential quotient of a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This document also provides materials and methods for screening factors that enhance maturation or myelination efficiency of an induced pluripotent stem cell-derived oligodendrocyte precursor cell or cells.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 7, 2024
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Charles L. Howe, Miranda M. Standiford, Kanish Mirchia
  • Publication number: 20240075074
    Abstract: The subject invention provides a method for promoting wound healing in a patient in need thereof comprising contacting a wound of the patient with exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) so as to thereby promote wound healing in the patient. The subject application also provides a method for promoting wound healing in a patient in need thereof comprising contacting a wound of the patient with a composition comprising one or more miRNA and a pharmaceutically acceptable carrier so as to thereby promote wound healing in the patient.
    Type: Application
    Filed: June 1, 2023
    Publication date: March 7, 2024
    Inventors: Lino da Silva Ferreira, Joana CORREIA, Renato Manuel Soares CARDOSO, Maria Helena Henriques Antunes
  • Publication number: 20240075075
    Abstract: This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1+ multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 7, 2024
    Applicant: Mesoblast, Inc.
    Inventor: Peter Ghosh
  • Publication number: 20240075076
    Abstract: In alternative embodiments, provided are products of manufacture for microbiome transplantation and engraftment, including fecal microbiota transplantation (FMT) delivery devices, and methods for using them, including methods for replacing an individual's gastrointestinal (GI), e.g., colonic, microbiome, and methods for the treatment, amelioration or prevention of an in situ microbiome space, or a gastrointestinal (GI) disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., pathological GI or colonic microbiome.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 7, 2024
    Inventors: Antony MILIS, Thomas Julius BORODY
  • Publication number: 20240075077
    Abstract: Bacillus strains useful for preventing and/or controlling Clostridium perfringens infections and necrotic enteritis in monogastric animals, such as swine and poultry, and for improving the overall health, feed conversion rates and body weight gain of such animals, as well as compositions comprising the Bacillus strains and various methods of using the Bacillus strains in animal feed and animal feed additives.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 7, 2024
    Applicant: Novozymes A/S
    Inventors: Derrick Lewis, Marianne Thorup Cohn, Adam Nelson, Preben Nielsen
  • Publication number: 20240075078
    Abstract: Methods of using Bacillus subtilis probiotic supplementation to promote lower circulating TNF-? in resistance trained males are presented. Methods of administering Bacillus subtilis probiotic supplementation to an athletic population in conjunction with a sound nutrition and training regimen are presented herein. College athletes typically undergo periods of elevated stress both physically and mentally which may negatively affect recovery and adaptation. 12-weeks of probiotic supplementation resulted in attenuated circulating TNF-? concentrations in college athletes following offseason training.
    Type: Application
    Filed: November 14, 2023
    Publication date: March 7, 2024
    Applicant: Deerland Enzymes, Inc.
    Inventors: John Deaton, Ana Maria Cuentas
  • Publication number: 20240075079
    Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.
    Type: Application
    Filed: September 28, 2022
    Publication date: March 7, 2024
    Inventors: Steven D. Goodman, Lauren O. Bakaletz, Michael Bailey, Gail Besner
  • Publication number: 20240075080
    Abstract: This invention relates to use of a strain of lactic acid bacteria for inhibiting the growth of methane-producing bacteria and/or archaea in the forestomach of ruminant animals, reducing the ability of the rumen microbiome to produce methane, reducing ruminal methane production and/or for improving feed efficiency, milk production, and/or body weight or body composition of a ruminant animal. Ruminant feed compositions are also provided.
    Type: Application
    Filed: December 22, 2021
    Publication date: March 7, 2024
    Inventors: Graeme Trevor Attwood, Laureen Crouzet, Shalome Anitta Bassett, James William Dekker, Jeremy Paul Hill
  • Publication number: 20240075081
    Abstract: An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 7, 2024
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Ayatake NAKANO, Takehiko YASUEDA, Yasuyuki SETO
  • Publication number: 20240075082
    Abstract: Provided is a composition including a lactic acid bacterium and a carrier thereof for prophylaxis or treatment of an allergy. The lactic acid bacterium is Lactobacillus paragasseri, such as Lactobacillus paragasseri BBM171 deposited under DSMZ Accession No. DSM 34311. Also provided is a method for preventing or treating an allergy in a subject that includes administering an effective amount of the composition of Lactobacillus paragasseri to the subject.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 7, 2024
    Inventors: Ying-Chieh Tsai, Yu-Hsuan Wei, Chih-Chieh Hsu, Chien-Chen Wu
  • Publication number: 20240075083
    Abstract: The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.
    Type: Application
    Filed: October 25, 2023
    Publication date: March 7, 2024
    Inventors: Nicholas T. MONSUL, Eva A. BERKES, Frederick T. BOEHM, Yu-Hsien LIAO
  • Publication number: 20240075084
    Abstract: A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Klebsiella pneumoniae, wherein at least one of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-30. Uses thereof are also disclosed.
    Type: Application
    Filed: January 20, 2022
    Publication date: March 7, 2024
    Applicant: Biomx Ltd.
    Inventors: Eyal WEINSTOCK, Iddo Nadav WEINER, Maya KAHAN-HANUM, Efrat KHABRA, Noa BEN-YISHAI, Dana INBAR, Rotem EDGAR
  • Publication number: 20240075085
    Abstract: The present invention relates to compositions, methods, uses and kits for combination therapies involving immunotherapies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the cancer is a solid tumor or a hematological malignancy.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 7, 2024
    Inventors: Niels HALAMA, Dirk JÄGER, Patrick SCHMIDT
  • Publication number: 20240075086
    Abstract: The present invention discloses a composition comprising sugar alcohols or a combination of sugar alcohols and a Tetraselmis extract or either of the former together with niacinamide for treating or preventing dysfunctions of the human hair or skin or as a skin or hair care product.
    Type: Application
    Filed: September 11, 2023
    Publication date: March 7, 2024
    Inventors: Martina Herrmann, Sandra Gaebler, Dominik Stuhlmann, Ann-Christin Weseloh
  • Publication number: 20240075087
    Abstract: This disclosure relates to non-naturally occurring or engineered compositions and methods comprising one or more hemp extracts for the treatment of diseases, disorders, syndromes, and/or conditions in animals in need.
    Type: Application
    Filed: August 2, 2023
    Publication date: March 7, 2024
    Inventor: Joseph Wakshlag
  • Publication number: 20240075088
    Abstract: The present disclosure generally relates to compositions of decaffeinated caffeoylquinic acid botanical extracts, and to methods of removing extracting a bioactive compound from a plant material. In some embodiments, the methods include obtaining a plant material; mixing the plant material with a natural deep eutectic solvent (NaDES); obtaining a crude extract solution comprising extracts of the plant material, the bioactive compound, and NaDES; loading the crude extract solution onto a macroporous resin; and recovering plant extract from the macroporous resin, wherein the bioactive compound and NaDES have been removed from the plant extract. In some embodiments, the bioactive compound is caffeine. In some embodiments, the plant material is obtained from yerba mate.
    Type: Application
    Filed: August 30, 2023
    Publication date: March 7, 2024
    Inventor: Dan Li